Understanding how T cell receptors recognize tumor antigens
Official title: MATCHMAKERS - SOLVING TCR RECOGNITION AND DESIGN VIA INTEGRATED HIGH-THROUGHPUT SCREENING, STRUCTURAL, FUNCTIONAL, AND COMPUTATIONAL APPROACHES
Funded at Oslo University Hospital, Rikshospitalet · NIH-11046747 · Data updated 2026-11-12
This study is looking at how T cells, which help our immune system fight cancer, recognize specific markers on tumors, and it's using smart computer techniques to make better predictions about how these T cells can be designed to work more effectively in cancer treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oslo University Hospital, Rikshospitalet NIH-funded |
| Lab location | 1 site (Oslo, Norway) |
| Project start | May 1, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $74,043 |
| NIH project number | 1OT2CA297513-01 |
| Project ID | NIH-11046747 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that have specific tumor antigens that can be targeted by T cell receptors.
✕Less likely to help
Patients with non-cancerous conditions or those whose tumors do not express identifiable antigens may not benefit from this research.
What this research studies
This research investigates how T cell receptors (TCRs) identify tumor antigens presented by MHC molecules, which is crucial for enhancing the effectiveness of immunotherapy. By integrating advanced machine learning techniques with extensive datasets of TCR-pMHC pairs, the project aims to develop accurate predictors of TCR-antigen recognition. The research involves generating large-scale datasets from both human and mouse models, focusing on cancer and immune responses. This collaborative effort combines expertise in immunology, structural biology, and computational methods to improve TCR design and prediction.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for cancer patients by improving the targeting of T cell receptors to tumor antigens.
How similar studies have gone: Previous research has shown promise in using machine learning and computational models to enhance immunotherapy, indicating that this approach could yield significant advancements.
Where this research is happening
-
Oslo University Hospital, Rikshospitalet
Oslo, Norway Active
Researchers
- Principal investigator: Olweus, Johanna — Oslo University Hospital, Rikshospitalet
- Study coordinator: Olweus, Johanna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.